Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Momelotinib

            Therapeutic Area: Oncology Product Name: GS-0387

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 11, 2021

            Details:

            Data highlights improved transfusion independence of momelotinib irrespective of baseline degree of anemia, platelet count or transfusion status. Efficacy data examining the association between transfusion independence and overall survival for momelotinib.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lutetium–177 Octreotate

            Therapeutic Area: Oncology Product Name: Lu-DOTATATE

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Point Biopharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 12, 2021

            Details:

            POINT Biopharma has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium–177 Octreotate for the treatment of neuroendocrine cancer. Lu-DOTATATE as it is being used in 167 neuroendocrine tumor patients in a 180-patient trial.